TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Alpha Teknova, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.80−0.28 (-3.95%)
Close on Oct 19, 2026
- Market cap
- $364.72M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
33.2%−23.6 pts over 5 years
Operating margin
-41.9%−56.8 pts over 5 years
Net margin
-42.6%−54.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +7.4% | -0.7% | +5.3% | – | |
| Gross profit | +85.9% | -8.4% | -5.4% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 24.1% | -22.8% | |
| Return on assets | – | – | -15.5% | |
| Current ratio | – | 4.14 | 4.58 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Inventory turnover | – | – | 3.9× | |
| Capex to revenue | – | 17.5% | 2.8% | |
| Diluted shares | – | 4M | 53M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alpha Teknova generated $76.32M from operations and spent $58.23M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$76.32M
Used
$58.23M
Capital expenditure$58.23M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-42.6%
×Asset turnover0.36×
×Equity multiplier1.47×
=Return on equity, FY2025-22.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -42.6% | 0.36× | 1.47× | -22.8% |
| FY2024 | -70.9% | 0.31× | 1.43× | -31.0% |
| FY2023 | -100.3% | 0.26× | 1.48× | -38.7% |
| FY2022 | -114.6% | 0.26× | 1.31× | -39.1% |
| FY2021 | -26.6% | 0.32× | 1.43× | -12.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$17.26M
- Cash generatingOperating cash flow above zero-$8.65M
- Return on assets improvedROA up on the prior year-20.8% → -14.5%
- Earnings backed by cashOperating cash flow above net income-$8.65M vs -$17.26M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.82 → 4.58
- No dilutionShare count did not rise47M → 53M
- Gross margin improvedGross margin up on the prior year19.16% → 33.17%
- More efficientAsset turnover rose0.29 → 0.34